Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799903 · ClinicalTrials.gov registry record · Phase 3
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 15,828
- Enrollment target
NCT00799903 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 15,828 participants.
The verdict
NCT00799903, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15,828 participants
- Enrollment target
Study Summary
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
Interventions
- DRUG Placebo
- DRUG Darapladib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,828 participants |
| Start Date | 2008-12-01 |
| Est. Completion | 2013-10-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799903
The ClinicalTrials.gov registry entry for NCT00799903 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 15,828 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00799903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00799903 about?
NCT00799903 is a clinical study titled "The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial". This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
What is the current status of trial NCT00799903?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15,828 participants. The study started on 2008-12-01. Estimated completion is 2013-10-17.
What interventions are being tested in trial NCT00799903?
The interventions under investigation include: Placebo (DRUG), Darapladib (DRUG).
Who is sponsoring clinical trial NCT00799903?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.